First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

Ou, Sai-Hong Ignatius; Jänne, Pasi A.; Leal, Ticiana A.; Rybkin, Igor I.; Sabari, Joshua K.; Barve, Minal A.; Bazhenova, Lyudmila; Johnson, Melissa L.; Velastegui, Karen L.; Cilliers, Cornelius; Christensen, James G.; Yan, Xiaohong; Chao, Richard C.; Papadopoulos, Kyriakos P.

doi:10.1200/jco.21.02752

First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1)

PURPOSE Adagrasib (MRTX849) is an oral, highly selective, small-molecule, covalent inhibitor of KRAS G12C . We report results from a phase I/IB study of adagrasib in non–small-cell lung cancer, colorectal cancer, and other solid tumors harboring the KRAS G12C mutation. MATERIALS AND METHODS Patie…